Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of lapatinib ditosylate and Akt
inhibitor MK2206 in treating women with metastatic breast cancer. Lapatinib ditosylate and
Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.